154061-64-0

Upstream product

• 2212-75-1 N₂-[(benzyloxy)carbonyl]-L-lysine 
• 501-53-1 benzyl chloroformate 
• 121895-18-9 (S)-2-amino-6-hydroxyhexanoic acid methyl ester hydrochloride 
• 110-87-2 3,4-dihydro-2H-pyran 
• 44601-24-3 4-hydroxypentanal 
• 102922-72-5 (S)-2-(((benzyloxy)carbonyl)amino)-6-hydroxyhexanoic acid 
• 74-88-4 methyl iodide 
• 52192-32-2 (S)-6-acetoxy-2-(benzyloxycarbonyl)aminohexanoic acid 
• 186581-53-3 diazomethane 

Downstream Products

• 357278-12-7 (S)-(+)-methyl-2-{[(benzyloxy)carbonyl]amino}-6-iodohexanoate 
• 227758-97-6 (2S)-3,4-dihydro-2H-pyridine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 824943-45-5 (2S,5R)-5-hydroxy-6-methoxy-piperidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 117836-13-2 (S)-5-Oxo-piperidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester 
• 917507-80-3 (2S,5S)-N-[(benzyloxy)carbonyl]-5-hydroxy-2-piperidinecarboxylic acid 
• 117836-26-7 cis-5(S)-hydroxy-2(S)-N₁-benzyloxycarbonylpipecolic acid methyl ester 
• 63088-78-8 (2S,5R)-5-hydroxypiperidine-2-carboxylic acid 
• 154061-66-2 N^α-(Benzyloxycarbonyl)-N^ε-(p-bromophenyl)-L-lysine methyl ester 
• 154061-69-5 N^α-Acetyl-N^ε-(p-bromophenyl)-L-lysine methyl ester 
• 35677-83-9 methyl (S)-pipecolinate 
• 357278-13-8 (S)-(+)-methyl-2-{[(benzyloxy)carbonyl]amino}-6-{[(tert-butoxycarbonyl)amino]oxy}hexanoate 
• 154061-65-1 (2S)-2-<(Benzyloxycarbonyl)amino>-6-bromohexanoic acid methyl ester 

Relevant academic research and scientific papers

Selective Targeting of AF9 YEATS Domain by Cyclopeptide Inhibitors with Preorganized Conformation

YEATS domains are newly identified epigenetic "readers"of histone lysine acetylation (Kac) and crotonylation (Kcr). The malfunction of YEATS-Kac/Kcr interactions has been found to be involved in the pathogenesis of human diseases, such as cancer. These di

MANUFACTURING METHOD OF (2S,5S)-5-HYDROXY-2-PIPERIDINECARBOXYLIC ACID AS WELL AS MANUFACTURING INTERMEDIATE OF THE SAME AND METHOD FOR MANUFACTURING THE SAME

PROBLEM TO BE SOLVED: To provide synthesis methods of 5-hydroxy-6-methoxypiperidine-2-carboxylic acid derivatives and 5-oxopiperidine-2-carboxylic acid derivatives more safely than ever by using inexpensive raw ingredients. SOLUTION: In the provided method, a compound expressed by the following formula [X] is manufactured from a compound expressed by the following formula [I] through steps (1) through (9) [either steps (4) and (5) or steps (6) and (7) in the case of steps (4) through (7)]. COPYRIGHT: (C)2015,JPOandINPIT

Synthesis of (S)-(+)-2-amino-6-(aminooxy)hexanoic acid

(S)-(+)-2-Amino-6-(aminooxy)hexanoic acid (AAHA, 3), a non-proteinogenic amino acid, and its derivative, (S)-(-)-6{[(tert-butoxycarbonyl)amino]oxy}-2-{[(9H-fluoren-9-ylmethoxy) carbonyl]amino}hexanoic acid (4), were synthesized from (S)-(-)6-amino-2-{[(be

Stereospecific synthesis of the anaesthetic levobupivacaine

Enantiomerically pure (S)-bupivacaine is synthesized from the chiral pool using cheap and readily available (S)-lysine. The key steps in this efficient synthesis include an oxidative de-amination and stereospecific ring closure to form the pipecolamide core structure.

Synthesis of N(ε)-(p-bromophenyl)-L-lysine and N(τ)-(p-bromophenyl)-L-histidine as models for adducts of bromobenze 3,4-oxide to protein. Observation of an unusual Pd-catalyzed N(τ)- to N(π)-aryl substituent migration

Bromobenzene 3,4-oxide (1), the putative toxic metabolite of bromobenzene, is known to alkylate protein sulfur nucleophiles in vivo and is postulated to alkylate protein nitrogen nucleophiles, the expected products of which would include, after hydrolysis